Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AC Immune stock | $6.41

Own AC Immune stock in just a few minutes.

Fact checked

AC Immune SA is a biotechnology business based in the US. AC Immune shares (ACIU) are listed on the NASDAQ and all prices are listed in US Dollars. AC Immune employs 115 staff and has a market cap (total outstanding shares value) of USD$395.3 million.

How to buy shares in AC Immune

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for AC Immune. Find the stock by name or ticker symbol: ACIU. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AC Immune reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$6.41, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of AC Immune, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of AC Immune. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

AC Immune share price

Use our graph to track the performance of ACIU stocks over time.

AC Immune shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$6.41
52-week rangeUSD$4.07 - USD$10.14
50-day moving average USD$5.2388
200-day moving average USD$6.2518
Wall St. target priceUSD$12.15
PE ratio 11.6316
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.547

Buy AC Immune shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AC Immune stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AC Immune price performance over time

Historical closes compared with the close of $6.41 from 2021-01-11

1 week (2021-01-11) 6.41
1 month (2020-12-18) 16.76%
3 months (2020-10-16) 31.35%
6 months (2020-07-17) -22.58%
1 year (2020-01-17) -30.33%
2 years (2019-01-18) -43.47%
3 years (2018-01-18) 13.06
5 years (2016-01-15) N/A

Is AC Immune under- or over-valued?

Valuing AC Immune stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AC Immune's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AC Immune's P/E ratio

AC Immune's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, AC Immune shares trade at around 12x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

AC Immune financials

Gross profit TTM USD$60.6 million
Return on assets TTM -13.25%
Return on equity TTM -23.54%
Profit margin 0%
Book value $2.986
Market capitalisation USD$395.3 million

TTM: trailing 12 months

Shorting AC Immune shares

There are currently 1.5 million AC Immune shares held short by investors – that's known as AC Immune's "short interest". This figure is 11% down from 1.7 million last month.

There are a few different ways that this level of interest in shorting AC Immune shares can be evaluated.

AC Immune's "short interest ratio" (SIR)

AC Immune's "short interest ratio" (SIR) is the quantity of AC Immune shares currently shorted divided by the average quantity of AC Immune shares traded daily (recently around 253685.88640275). AC Immune's SIR currently stands at 5.81. In other words for every 100,000 AC Immune shares traded daily on the market, roughly 5810 shares are currently held short.

However AC Immune's short interest can also be evaluated against the total number of AC Immune shares, or, against the total number of tradable AC Immune shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AC Immune's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 AC Immune shares in existence, roughly 20 shares are currently held short) or 0.0476% of the tradable shares (for every 100,000 tradable AC Immune shares, roughly 48 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AC Immune.

Find out more about how you can short AC Immune stock.

AC Immune share dividends

We're not expecting AC Immune to pay a dividend over the next 12 months.

AC Immune share price volatility

Over the last 12 months, AC Immune's shares have ranged in value from as little as $4.07 up to $10.14. A popular way to gauge a stock's volatility is its "beta".

ACIU.US volatility(beta: 0.83)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AC Immune's is 0.8292. This would suggest that AC Immune's shares are less volatile than average (for this exchange).

AC Immune overview

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site